PTGX

Over the past six months, Protagonist Therapeutics' stock price has been impacted by several significant events. The company reported strong Q1 2026 earnings, exceeding analysts' expectations. Protagonist exercised its U.S. opt-out right on rusfertide, triggering a $200 million payment. Johnson & Johnson received FDA approval for Icotyde (icotrokinra). Following these positive developments, several research firms upgraded their ratings and increased price targets for PTGX. In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. The company's shares have risen more than 120% in the past year.